5890976
Last Update Posted: 2025-03-05
Recruiting has ended
All Genders accepted | 18 Years + |
200 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)
This study is being conducted to see if semaglutide tablets can be used as a treatment to help people who are above a healthy weight range to lose weight. Semaglutide tablets are a new medicine being tested to treat people living with excess body weight. Participants will either get semaglutide or placebo once daily morning for 44 weeks.
In addition to taking the medicine, participants will have talks with study staff about:
- Healthy food choices
- How to be more physically active
- What participants can do to lose weight This study will last for about 1 year.
Eligibility
Relevant conditions:
Overweight
Obesity
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Novo Nordisk
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Data sourced from ClinicalTrials.gov